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Abstract: Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest worldwide. All
three of the Human Papillomavirus (HPV) vaccines (9-valent, quadrivalent and bivalent HPV vaccine)
provide primary protection against the most common cancer-causing strains of HPV (types 16 and 18)
that are known to cause 70% of cervical cancers. Over the last five years, there has been an increase
in Sub-Saharan African countries that have introduced the HPV vaccine. The majority of research
has been conducted on supply-side barriers and facilitators to HPV vaccination uptake in SSA, yet
little research has been conducted on demand-side or end-user perspectives of, and decisions around,
HPV vaccination. In order to complement existing research, and inform current and future HPV
vaccination implementation approaches, this qualitative systematic review explored Stakeholders’
understandings of HPV vaccination in SSA. This review searched the following databases: Embase
(via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic Search Premier,
Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and
the Cochrane Controlled Register of Trials (CENTRAL) and found a total of 259 articles. Thirty-one
studies were found eligible for inclusion and were analyzed thematically using Braun and Clarke’s
methods for conducting a thematic analysis. The quality of included studies was assessed using
the Critical Appraisal Skills Programme (CASP) checklist. Three major themes emerged from this
analysis; knowledge of HPV vaccination and cervical cancer is intertwined with misinformation; fear
has shaped contradictory perceptions about HPV vaccination and gender dynamics are relevant in
how stakeholders understand HPV vaccination in SSA.
Keywords: Human Papillomavirus (HPV); vaccination; Sub-Saharan Africa (SSA); stakeholder
understandings; rapid qualitative systematic review; thematic analysis
1. Introduction
Human papillomavirus (HPV) is a central causative agent of cervical cancer, the
second most common cancer among women in Africa, where approximately 372.2 million
women aged 15 years and older are at risk of developing cervical cancer [1]. There are
more than 100 types of HPV, at least 14 of which are high-risk strains that can cause cancers
of the vulva, vagina, penis, anus, oropharynx and most commonly the cervix [2–4]. Such
strains are commonly sexually transmitted an are highly transmissible through skin-to-skin
genital contact, anal, oral and vaginal sex, with estimations that two thirds of those who
have had sexual contact with HPV-infected persons will become infected themselves [2,5],
making it the most common viral infection of the reproductive tract and the most common
sexually transmitted disease in the world [2,5,6].
The quadrivalent HPV vaccine was first approved by the U.S Food and Drug Adminis-
tration (FDA) in 2006, offering primary protection against the most common cancer-causing
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strains of HPV (types 6, 11, 16, 18) followed by the bivalent vaccine approved in 2009
(protection against type 16 and 18) (both are which are primarily used in SSA), and finally
the 9-valent vaccine approved in 2014 (providing protection against 6, 11, 16, 18, 31, 33, 45,
52, and 58). In SSA, late presentation to care is an established trend associated with health
inequities, gender disparities, socioeconomic and cultural factors that have ultimately
increased cervical cancer mortality rates [3,5]. The World Health Organization (WHO)
estimates that at least one third of all HPV-related cancers in Africa could be prevented
with comprehensive vaccination implementation [3].
As of June 2019, nine Sub-Saharan African countries have included HPV vaccination
in their National Immunization Programs (NIPs): Botswana (2015), Lesotho (2012), Rwanda
(2011), Sao Tome and Principe (2016), Senegal (2016), Seychelles (2014), South Africa (2014),
Uganda (2012), and Mauritius (2016) [1,7–9]. Twenty-two SSA countries have HPV vaccine
demonstration projects in place. These numbers are likely to increase considerably—over
the last 5 years, the Global Alliance for Vaccines and Immunization (GAVI), along with the
World Health Organization, PATH and UNICEF, has generated substantial momentum
around HPV vaccination in SSA [10].
In order for any type of vaccination to be successful, high levels of uptake are required
in order to promote herd immunity, a phenomenon where enough people in the population
are vaccinated and the pathogen cannot reproduce [11]. Despite a steady rise in the number
of African countries introducing HPV vaccination into National Immunization Programs
and demonstration/pilot projects, coverage is still suboptimal [8]. According to GAVI, all
five of the countries with the highest numbers of deaths from cervical cancer remain in SSA,
highlighting the major public health concern of the continued prevalence and incidence of
cervical cancer and the need for increased uptake of HPV vaccination in SSA [12].
HPV vaccination coverage in SSA is shaped by a range of factors [4]. The majority
of research in the region has tended to focus on health system and supply-side barriers,
including health system capabilities, inaccessibility to medical care, low cervical cancer
screening levels, inadequate infrastructure, finances, and health worker training as signifi-
cant systemic barriers to HPV vaccination success [8,13–16]. However, there is growing
recognition that demand-side barriers may also be contributing to suboptimal HPV vac-
cination coverage in SSA [2,11,17]. Persistent skepticism around HPV vaccination has
contributed to stakeholder uncertainty in vaccination behavior and actual decision making
around the HPV vaccine. This has motivated further research into understanding why
people get vaccinated and why they do not, especially given “the incredible impact and
value that vaccination has had” and the continued lack of clarity around low levels of HPV
vaccination uptake in countries where it has become available and affordable [18].
This review focuses on the demand-side barriers and facilitators of HPV vaccination
by examining the perspectives and understandings of relevant stakeholders involved in
decision-making linked to the uptake of HPV vaccination in SSA. This review explores the
qualitative literature documenting the perspectives of adolescents, parents and caregivers,
teachers and health care providers, and political, community and religious leaders in
creating ‘demand’ for HPV vaccination. By exploring an ‘end-user’ or ‘demand-side’ point
of view from these stakeholders, valuable insight into factors that promote or inhibit HPV
vaccination efforts in SSA may become clearer. Utilizing empirical qualitative evidence
from various demand-side stakeholders’ perspectives will more accurately reflect the
spectrum of HPV vaccination behavior and decision-making in SSA.
2. Materials and Methods
2.1. Review Question, Aims and Objectives
This rapid systematic review explored how stakeholders understand the HPV vaccine
and HPV vaccination in SSA. The key objectives included identifying, appraising and
synthesizing the qualitative evidence of stakeholders understandings, experiences, and
perceptions of the HPV vaccine and HPV vaccination in SSA in order to complement
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reviews on HPV vaccine effectiveness and contribute to understandings of the barriers and
facilitators of successful implementation of HPV vaccination strategies in SSA [19].
2.2. Search Strategy
This review conducted systematic and comprehensive searches during March and
April 2019 using the following relevant databases: Embase (via Scopus), Scopus, MEDLINE
(via PubMed), PubMed, EBSCOhost, Academic Search Premier, Africa-Wide Informa-
tion, CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and the Cochrane
Controlled Register of Trials (CENTRAL). The search terms related to HPV and the HPV
vaccine, terms related to comprehension and understandings, terms related to SSA, and
terms related to qualitative research (Appendix A). The reference lists of systematic reviews
identified through the database searches were scanned in order to identify additional
relevant papers.
2.3. Inclusion and Exclusion Criteria
This review sought studies on stakeholder ‘understandings’ of the HPV vaccine in SSA,
broadly defined, including studies on understandings, experiences, perceptions, attitudes,
beliefs, knowledge, comprehensions, feelings, and opinions of the HPV vaccine in SSA.
The population of interest included relevant stakeholders who create a ‘demand’ for the
vaccine including adolescents, parents and caregivers of adolescents, teachers, health care
providers, and political, religious, and community leaders.
Eligible research articles took place in SSA and were published in English from 2006
(when the first HPV vaccine Gardasil was manufactured)-present. Eligible articles used
a qualitative or mixed methods study design, where both data collection and analysis
employed qualitative methods.
Studies outside of SSA were excluded. Studies examining HPV-related health out-
comes, or vaccination more generally without a specific focus on the HPV vaccine, were
also excluded, as were quantitative studies and systematic reviews. Grey literature and
non-English studies were excluded.
2.4. Study Selection
Studies were selected through a 4-stage process where titles and abstracts were iden-
tified through hand and database searches and were then screened for eligibility by one
author. To maintain rigor, 20% of eligible title and abstracts were screened by two indepen-
dent reviewers and were reviewed for full text eligibility. A final list of eligible studies was
collated and uploaded into Covidence software for quality assessment and data extraction.
The search process is outlined in the PRISMA diagram (Figure 1) and the included studies
were mapped (Figure 2).
2.5. Data Extraction
Qualitative data from each study were extracted into a Microsoft Excel sheet. Relevant
contextual information from each study was also extracted, including first author name,
year of study, year of publication, the country where the study took place, the study
participants, the qualitative data collection and analysis methods, and the aim of the study
(Appendix B).
2.6. Study Quality Assessment
All included studies were assessed by lead author (CD) using the Critical Appraisal
Skills Programme (CASP) appraisal tool for quality assessment purposes. The CASP
checklist includes the following criteria: aims of the research question, the qualitative
methodology, the research design, the recruitment strategy, data collection, reflexivity,
ethical issues being considered, data analysis and findings being of substantial value and
evidence. Studies were not excluded based on the CASP appraisal tool assessment alone
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(Appendix C), but this assessment informed the analyses and overarching findings of the
review.
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2.7. Data Extraction and Analysis
A thematic analysis approach, as described by Braun and Clarke (2006), was used to
synthesize the data. Thematic analysis develops and organizes findings into themes using
inductive and ‘constant comparison’ methods and is an appropriate synthesis method
for exploring questions about people’s perspectives and understandings [21,22]. The
overall themes and the components of each individual theme (made up of sub-themes)
were confirmed and named. This contributed to the greater narrative of stakeholder
understandings, experiences and perceptions of the HPV vaccine in SSA. The analysis
of this review identified potentially relevant themes, schools of thought and actions for
consideration of HPV vaccination roll out based on the contexts in which the studies
took place.
3. Results
After deduplication, abstract and title screening and full text screening, thirty-one
eligible studies were included in the review.
3.1. Study Characteristics
As shown in Figure 2, the majority of included studies came from Eastern and Southern
Africa, predominately from Uganda, Kenya, and South Africa. All of the studies utilized
focus group discussions or interviews (or both) for data collection methods. Thematic,
comparative analysis, narrative synthesis, grounded theory and content analysis were the
four methods of data analysis across studies (Appendix B for more information about the
studies).
3.2. Findings
Please see Summary of themes and findings in Table 1.
Table 1. Summary of themes and findings.
Theme Main Points:
Theme 1: Knowledge and
misinformation
- Generally low levels of technical knowledge about cervical cancer and HPV in SSA
-Knowledge and misinformation about cervical cancer and the HPV vaccine exist in
parallel and cause confusion in stakeholder perceptions of HPV vaccination
-Cervical cancer is widely feared and stakeholders expressed clear desires to avoid a
cerivcal cancer diagnosis
- There were significant social layers of influence on stakeholder perceptions about HPV
vaccination, as well as actions and attitudes that impact HPV vaccination behaviour
- Misinformation circulating in some countries acted as both a facilitator and a barrier to
the uptake of the HPV vaccine
Theme 2: Fear of infertility shaping
contradictory perceptions of HPV
- Fear of infertility was the most salient theme in stakeholders’ narratives about cervical
cancer and HPV vaccination
- Two predominant narratives prevailed in relation to the etiology of infertility in relation
to cervical cancer and the HPV vaccine. Some believed infertility was a result of cervical
cancer, while others believed infertility was a result of receiving the HPV vaccine
Theme 3: The feminization of HPV
vaccination in SSA
- Gender dynamics featured in stakeholder narratives about HPV vaccination Programs
and HV vaccination decision-making.
- HPV is a gender-neutral virus, yet several stakeholders were confused why HPV
vaccination is solely directed at females in the SSA context
-Health seeking behaviour around HPV vaccination is often influenced by gender
dynamics
-In general, male and female stakeholders across studies urged for males to be included
in education around cervical cancer and HPV vaccination
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3.3. Theme 1: Knowledge and Misinformation
Stakeholders have knowledge but also misinformation in relation to understandings
of cervical cancer risks and transmission that shape perceptions of HPV vaccination as a
whole. This knowledge and misinformation has left many stakeholders uncertain about
how to understand and make decisions linked to HPV vaccination.
3.4. Understandings and Perceptions of Cervical Cancer and Its Causes
There were generally low levels of technical knowledge about cervical cancer and
HPV in SSA [14,23–27]. This was most evident in stakeholders not knowing that HPV is
the causative agent of cervical cancer, followed by stakeholder confusion and uncertainty
around which part of the female reproductive tract is affected by cervical
cancer [14,15,25,26,28–30], further evidenced in the quote, “I have never heard about cancer of
the cervix. What is the difference between the cervix and the uterus? We thought it was the same
thing” from one female interviewed in Uganda [31]. In general, stakeholders seldom made
distinctions between the cervix, uterus, and womb when discussing cervical cancer, most of-
ten referred to as ‘cancer of the womb’ in South Africa, Kenya, and Uganda [14,15,23,31–33].
Across studies, “cancer of the uterus” was the second most common reference to cervical
cancer, highlighting explicit confusion between the cervix and the uterus [13,23,29,31,34].
How people speak about a health topic is often a good indication of what they
understand about it [35]. When stakeholders were asked what they knew about cervical
cancer, responses consistently included explanation or recognition of the disease through
perceived symptoms (accurate or inaccurate), rather than the use of correct terminology
to name the disease and its cause, emphasizing nuances in local language [31]. Further
evidence of stakeholder confusion around cervical cancer and its causes were evident in
some stakeholders explaining they feel they are “in the dark” about HPV and are anxious
to know more about it [14,26].
The majority of stakeholders across included studies had limited technical knowledge
about cervical cancer and HPV. Many were aware that HPV is sexually transmitted and
cited common symptoms of cervical cancer including vaginal bleeding, foul odor, vaginal
discharge, and pain during intercourse [26,36–38]. Few stakeholders, usually health care
providers, clinicians, and educators, were aware that HPV can be a silent infection that
affects men and women alike [25,36,39]. Stakeholders often insinuated that promiscuity
and poor hygiene were the cause of cervical cancer [23,25,30,37]. As a Nigerian male
religious leader explained, “If a woman has sex anyhow with different men, it can cause cancer...
If you sleep with 5 men that is 5 different diseases, 8 men means 8 different diseases . . . . So, if
a woman sleeps around she can have cervical cancer” [25]. Others attributed sexual activity
to the accumulation of sexually transmitted infections, that when left untreated, cause a
block in a woman’s reproductive tract that produces cancer from a “combination of several
diseases” [23].
Stakeholders who personally knew someone with cervical cancer were less likely
to link cervical cancer aetiology to promiscuity. Some expressed cognitive dissonance
in knowing “conservative” women who were diagnosed with cervical cancer [23,25].
Additional skepticism around a male being an asymptomatic carrier of HPV added to
confusion around the causes of cervical cancer and the aetiological link to HPV [23,25].
Other perceived or hypothesized causes that stakeholders attributed to cervical cancer
were: a modern lifestyle of processed food and reliance on medication [23,25,31], genet-
ics [23,25,40], witchcraft [37], vaginal insertion of drugs [26,37], progression of existing
STDs [23], lack of cleanliness [33], having sex while menstruating [33], penile impuri-
ties [33], poor sexual habits [37] and frequent childbirth or frequent abortion [26].
3.5. Understandings of the Risks for HPV and Cervical Cancer
Cancer in general was widely feared and stigmatized by participants across
studies [14,25,26,33,41]. When asked about perceptions of cervical cancer, stakeholders
across studies described it as “painful”, “dangerous”, “horrible”, “incurable”, “deadly”,
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and a “death sentence” [29,30,33,38]. Words like “death”, “suffering”, “pain”, and “re-
duced quality of life” were commonly associated stakeholders talking about a cervical
cancer diagnosis [14,25,26,41]. Such perceptions were often based on stakeholders’ experi-
ence of knowing someone with cervical cancer and having watched them suffer from the
disease [14,23,25,29,30,38].
When discussing both cervical cancer diagnosis and HPV, stakeholders highlighted
fear as a predominant emotion [14,25,26,41]. The fear of cervical cancer was so great that
some women expressed reluctance to seek care, saying they would prefer “not to know” as
they believed cervical cancer would inevitably lead to death [38,41–43] evident in a female
participant in a focus group discussion in Uganda expressing: “I fear going for a check-up
since after getting the diagnosis of cervical cancer, I will then know that I am dying” [38]. This
was also supported in South Africa where women expressed that they would rather not
“face” the possibility of a cervical cancer diagnosis [44].
In most studies, female stakeholders perceived a high risk of cervical cancer for both
themselves and their female counterparts [30–32,38]. This risk perception was linked to
high rates of cervical cancer mortality in stakeholder’s country context, thus reinforcing a
clear desire from stakeholders (female and male) to avoid a cervical cancer diagnosis in
oneself and loved ones [14,15,25,26,29,30].
The fear of cervical cancer, the pain associated with it, and the desire to avoid it were
frequently mentioned across studies. This led stakeholders who understood the purpose
of HPV vaccination, to conduct a risk assessment, weighing up the short-term pain (of
the HPV vaccine injection) with long term pain (of potential cervical cancer diagnosis),
often reaching the conclusion that “prevention is better than cure” [14,15,25,26,29,30] with
a Ugandan female adolescent explaining “I have had injections before and I know the pain lasts
a short time but I feared that the pain from cancer can last forever” [29].
3.6. Understandings of HPV Vaccination
Across studies there was a lack of awareness that an HPV vaccine exists [14,15,25,26,28–30].
Despite low levels of baseline technical knowledge about the HPV vaccine, there was
notable willingness to learn more about HPV vaccination [14,24,29,45,46].
Preventing cancer was a large part of the rationale for getting vaccinated against HPV,
sometimes referred to as the “cancer of the womb vaccination” in countries such as South
Africa [14]. A Ugandan adolescent female explained: “People say that cancer has no cure
but the health worker told us that this cancer [HPV] . . . could be prevented, so I was very happy
because it meant that if I got vaccinated I would not die of cancer” [29].
Although there was clear interest in preventing cervical cancer, many stakehold-
ers raised the point that without symptoms, they were unsure why HPV vaccination
was necessary, thus highlighting a lack of knowledge around the notion that vaccines
prevent the onset of disease. This sentiment was especially evident in one participant
from a focus group in Kenya who asked: “What are you vaccinating us against, yet we are
not sick?” [28] which reinforced symptomology as a driver in health seeking
behavior [36–38]. Without tangible symptoms, stakeholder action towards vaccination
uptake may be inhibited, illustrated by a policy maker in Zambia who said: “[A woman]
will not go to the clinic unless she is sick . . . So expecting healthy people to voluntarily come
for vaccination is difficult” [37]. Delayed health seeking behavior, an established trend in
SSA, coupled with a lack of knowledge about the preventative nature of HPV vaccination,
largely contributed to stakeholders’ understandings of cervical cancer and the HPV vaccine
across studies [36–38].
There were significant social layers of influence on stakeholder perceptions about
HPV vaccination, as HPV vaccination behaviors, actions and attitudes are shaped by both
exposure to information and interaction with fellow community members [41]. Political
leaders, religious figures, community leaders, community elders, health care providers,
teachers, and peers all contributed to local behaviors and understandings related to HPV
vaccination [24,36,37,47,48]. A stakeholder spoke to the role of political influence on
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perceptions of HPV vaccination saying, “The former first lady [used to be] on television all
the time talking about cervical cancer and we had an overwhelming response . . . The [patients]
who were coming told us that [they] heard about it from the first lady” [37]. Other prominent
influential figures other than political leaders included religious leaders and community
leaders, with various stakeholders expressing that communal HPV vaccination acceptance
begins with such leaders [24,37,47,48]. One stakeholder also expressed the importance of
teachers saying, “ . . . a child does not doubt [a teacher]. They can go home and convince the parent
‘this is what the teacher said” [36]. Conversely, some adolescents said they would get the HPV
vaccine regardless of layers of social influence from parents and caregivers [26,29,48].
3.7. Understandings of How Misinformation Is Perpetuated
Sources where people seek information on HPV vaccination is relevant to the perpetu-
ation of misinformation. While factually inaccurate, misinformation circulating in some
countries acted as both a facilitator and a barrier to the uptake of the HPV vaccine. In one
focus group discussion with parents in Uganda, the notion that HPV vaccination could
protect people from other viruses, such as HIV, arose amongst stakeholders; “Since HPV and
HIV are both viruses, some people believed that HPV vaccination can also prevent HIV” [41]. Simi-
larly, the assumption that HPV vaccination could protect some girls from getting pregnant
was a reason one adolescent female cited as to why some girls get the HPV vaccine [41].
Although both of these beliefs are factually inaccurate, they facilitated the uptake of the
HPV vaccine. Conversely, misinformation also acted as a deterrent to the HPV vaccine,
evident in some people explaining that they could not get the HPV vaccine because “it
would damage the body” or cause “future disease from the chemicals the vaccine contains”,
harboring the belief that the HPV vaccine kills people slowly over time [25,41].
Misinformation characterized understandings of cervical cancer as well as HPV vac-
cination. Some stakeholders believed (and feared) that cervical cancer causes infertility,
while others believed (and feared) that the HPV vaccine causes infertility. Misinformation
was perceived to be perpetuated in communities in different ways; Nyambe and colleagues
attributed persistent misinformation in Zambia to low levels of social mobilization around
HPV vaccination, whereas Masika and colleagues attributed misinformation around HPV
vaccination in Kenya to a lack of uniform and top-down training of relevant stakeholders
ranging from policy makers, to health care providers, to teachers assisting with adminis-
tering the HPV vaccine [37,40]. Insufficient comprehensive training on HPV vaccination
further contributed to the gaps in rollout procedures and was considered to hinder the
success of school-based HPV vaccination Programs in Zambia, Kenya, Mozambique, and
Zimbabwe, where teachers (assisting health care providers administer the HPV vaccine to
adolescent girls) expressed how they did not receive sufficient information or training on
HPV vaccination [34,36,37,40,49]. Another female teacher from a different study in Kenya
suggested: “All teachers should be given the same information . . . For instance, in our district,
only the headteacher and two other teachers were called” [about HPV vaccination training] [40].
Improper training around HPV vaccination led to poor communication, which in
turn, perpetuated existing misconceptions about the HPV vaccine, inevitably introducing
or heightening skepticism, fear and uncertainty around HPV vaccination within com-
munities and even in the minds of key stakeholders such as health care providers and
teachers [23,34]. A lack of comprehensive information given to communities at the onset
of the introduction of HPV vaccination, almost always initiated and even expedited, the
spread of rumors and misinformation in its place [26,33,38,40]. Such misinformation in-
cluded distortion of technical facts such as appropriate dose schedule [29,50,51], rationale
for age of HPV vaccination initiation [26,49] and rumors on the preparedness and training
of vaccinators [15,34].
3.8. Theme 2: Fear of Infertility Shaping Contradictory Perceptions of HPV Vaccination
Fear of infertility was the most salient theme in stakeholders’ narratives about cer-
vical cancer and HPV vaccination [14,25,26,41]. Male and female stakeholders placed
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significant value on a woman’s ability to bear children [26,33,38,40,52], strongly fearing
infertility which was highly stigmatized and seen as a source of shame and lowered female
worth [26,33,38,40,52].
Two predominant narratives prevailed in relation to the etiology of infertility in
relation to cervical cancer and the HPV vaccine. Some believed infertility was a result of
cervical cancer [15,29,41,43] while others believed infertility was a result of receiving the
HPV vaccine [26,28,29,33,34]. These contrasting perspectives contributed to differing HPV
vaccination behaviors.
3.9. Perception That Infertility Is a Result of Cervical Cancer
Depending on the timing of presentation for care, type of HPV strain, severity of
symptoms, and progression of disease, cervical cancer can cause infertility in some cases,
but this is not a guarantee nor a norm [3,5]. Conversely, stakeholders in some studies be-
lieved that infertility was an inevitable outcome of cervical cancer [24,26,29,33,34,37,38,49].
A father in Kenya explained: “When one hears the term cervical cancer especially when your
child has it, you get scared. You then ask yourself whether she will ever give birth . . . Because when
she has cervical cancer, she might not give birth and will finally die, so a parent loses hope” [47].
Stakeholders with similar beliefs were in obvious support of HPV vaccination as a means
to prevent cervical cancer and by extension, infertility [24,26,29,33,34,37,38,49].
3.10. Perception That Infertility Is a Result of the HPV Vaccine
Conversely, other stakeholders believed HPV vaccination was the cause of infertil-
ity [26,28,29,33,34]. Although the origin of this belief could not be identified, it was highly
prevalent across studies and had significant influence on how some stakeholders’ perceived
HPV vaccination [26,28,29,33,34]. Fear that the HPV vaccine causes infertility was the most
prevalent justification for vaccine hesitancy, as evidenced in stakeholders expressing: “They
said it kills a woman’s eggs and she does not produce children . . . Some believed that the vaccine
was meant to reduce fertility of women in future by destroying their ovaries . . . ” [41].
These two schools of thought, that cervical cancer causes infertility amongst women
and conversely, that HPV vaccination causes infertility amongst women, did not seem to
overlap, and both weighed significantly in stakeholder decisions around HPV vaccination
in SSA [9,41,47].
The debate around the cause of infertility was further fueled by pertinent distrust of
both local health systems and governments, as well as international vaccine initiatives and
stakeholders from high-income countries who were perceived to be drive the roll out of
HPV vaccination in some studies [13,28,33,34]. As one participant explained: “What I have
heard about the vaccine . . . some say that it has been developed to reduce the population, to reduce
the fertility in a woman, an African woman” [34]. Some stakeholders in Zambia explained that
a lack of information given to them during the implementation of the HPV vaccination pro-
gram made them question how much research had been done on the HPV vaccine, whereas
some stakeholders in Uganda questioned whether HPV vaccination was an opportunity
for government to conduct research and “experimentation”, using young girls as “guinea
pigs” [13,37]. Others worried that HPV vaccination was just a government-supported
initiative for population control of Africans or that Africa was receiving “second-tier” or
“left over” vaccines from first world countries [15,33,37]. This sentiment of uncertainty was
echoed by several stakeholders across studies, making an underlying suspicion of public
health initiatives and widespread anti-fertility rumors a large factor when considering
HPV vaccination in SSA [15,26,33,37]. Mistrust and misinformation often left stakeholders
unsure of what to believe around HPV vaccination, best displayed in an adolescent female
from a focus group discussion in Uganda saying: “People say that the HPV vaccine may make
us fail to bear children in future; but we have also been told that it is not true that the injection can
cause infertility. So we do not know the truth” [41].
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3.11. Theme 3: The Feminization of HPV Vaccination in SSA
Gender dynamics, pertaining to HPV vaccination Programs, vaccination decision-
making and the contexts in which these occur, also featured prominently in
stakeholders’ narratives.
HPV vaccination Programs have traditionally only targeted female adolescents as
women account for most morbidity and mortality from HPV-related outcomes [33]. As
HPV is a gender-neutral virus, several stakeholders were confused by HPV vaccination
being solely directed at females [15,23,28,36] evident in a question asked by a public health
nurse in Kenya; “Why target women and not men? Why don’t you target the source? Why don’t
you put out the fire from where it starts?” [24].
Some male stakeholders expressed disinterest in HPV vaccination, assuming that
since it is a female-directed vaccine aimed at addressing cervical cancer, that HPV must
not affect men [15,23,36]. The focus on cervical cancer (and by extension, the necessity
of having a cervix in order to be directly affected), coupled with a traditional cultural
focus of reproductive health being a part of a “woman’s job”, reinforced feminization of
HPV and caused feelings of resentment, confusion, and distrust towards HPV vaccina-
tion from some stakeholders of both sexes in SSA [15,28]. Other stakeholders expressed
concern that just vaccinating girls was not only discriminatory, but also confusing for
boys, especially when trying to close the unequal gendered power dynamic in SSA [28,29].
Some stakeholders called for future vaccination campaigns to be gender-neutral and in
the interim, with concern about the progressively early age of sexual debut of male and
female adolescents, [15,28,41,48] for education campaigns to shift to a “gender-neutral
focus” to emphasize the gender neutrality of HPV infection amongst current generations
of adolescent males and females alike [23,43].
In some studies, female HPV vaccination was perceived to provide some protection in
environments where gender-based violence and abuse of female children and adolescents
was highly prevalent. For example, one female parent in South Africa said; “I feel certain
about [vaccinating my child] because there is AIDS and HIV out there and we all are aware of
it . . . My child can be raped, and I will feel bad about it, but I am at peace [knowing] that she is
participating in the Kganya Motsha [HPV vaccine trial] and will be protected against [this] sexually
transmitted disease” [48]. The inevitability of rape in South Africa was also mentioned in an
interview with a Sangoma [traditional healer] [32] and a father [48]. In this manner, the HPV
vaccine was seen as a harm reduction strategy against gender-based sexual violence, which
some stakeholders perceived as inescapable for females in some contexts [14,32,37,43,48].
Health-seeking behavior was also shaped by gender dynamics. In some countries
(Zambia, Zimbabwe, Kenya and Tanzania), men had the ultimate say in women’s health
decisions, including decisions around HPV vaccination [23,26,34,36,37]. One woman from a
focus group in Zambia explained this further: “[There is] the cultural background that a woman
should seek permission from her husband, whether she should take her daughter for the vaccine . . .
so those are cultural issues that will always be there” [34]. Some teachers in Tanzania agreed,
explaining that school meetings were not always successful when it came to educating
parents and caregivers about HPV vaccination for their adolescent daughters because
even if the mother was convinced to get the daughter vaccinated against HPV, many
fathers refused and had the final say in HPV vaccination uptake for their daughters [26].
The converse was true in South Africa and Malawi, where stakeholders agreed that the
responsibility for the care of children lay solely with women, including healthcare decisions
for children, while fathers and male kin were generally absent from the process [14,30].
In general, male and female stakeholders across studies urged men to be more included
in education around cervical cancer and HPV vaccination. In addition to men being
carriers of HPV and being susceptible to cancer outcomes such as anal, penile and throat
cancer [15,24], greater male involvement could help to reduce the stigma around HPV
vaccination that has been seen as a female responsibility and health issue [29]. This is
further evident in the quote by one female focus group participant in Zambia saying: “ . . .
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but with education we should include the male folk because mostly we side line them, [but] they also
play an important role” [34].
4. Discussion
Three major themes emerged from this review. Firstly, stakeholders’ understandings
and perceptions of cervical cancer, HPV and HPV vaccination are shaped by a mix of
knowledge and misinformation, both of which are influenced by social processes and
relationships and both of which act as both barriers and facilitators to HPV vaccination.
Within the broader literature, this review supports Abdullah and colleagues that there is
sub-optimal knowledge about vaccine preventable diseases and associated vaccines in
Africa, albeit moderate levels of positive attitudes towards HPV vaccination [46]. The
studies included in this review revealed that misinformation is fueled by both rumors and
fear, which simultaneously contribute to a growing suspicion and distrust of vaccination
Programs (in general and HPV vaccination specifically) in SSA. The issue of trust and dis-
trust has received considerable attention within the broader vaccination demand literature
in general, as well as in specific relation to HPV vaccination. In regard to vaccination in
general, broader qualitative research suggests that trust of the vaccine, the provider, and
the policy-maker are what drive vaccine acceptance and that perceived trust violations
often result in various ways, one of which from the perception that health care providers,
government or the wider health system financially profit from vaccination, leaving stake-
holders feeling like there is a hidden agenda in the suggestion to be vaccinated [53–55].
This broader research finding is relevant to the findings of this review, evident when some
stakeholders attributed their HPV vaccination hesitancy to skepticism of government and
health care providers intentions and agenda [26,28,29,33,34]. This idea contributes to the
greater findings of this review that there is an obvious social dimension to the exchange
of information around HPV vaccination, with special emphasis on sources of HPV vac-
cination information shaping how information is perceived. This finding supports the
broader literature on vaccination trust [53–57] and cut both ways in this review; some
stakeholders placed large trust and validation in a health care provider recommendation for
HPV vaccination, while others placed very little, or even diminished value, from the same
health care provider recommendation. Notable is the varying level of trust of government
and health care providers across stakeholders, with several stakeholders in this review
perceiving HPV vaccination to be a covert method of population control and thus having
a deep distrust of both the initiative of HPV vaccination and the health care providers
carrying it out [26,28,29,33,34]. Conversely, some stakeholders requested validation or
further information about HPV vaccination from community or religious leaders, whom
were often perceived as acting in the best interest of the community (and therefore de-
served trust), [24,36,37,47,48] often being suggested as figures to publicly endorse HPV
vaccination programs to potentially mitigate non-acceptability barriers such as doubts
about HPV vaccination efficacy and fear of safety and side effects [54]. These underlying
dynamics need to be both identified and better understood. The disconnect in where and
whom stakeholders choose to place their trust is notable, especially considering distrust of
HPV vaccination has led to further misinformation and has left many stakeholders unable
to ascertain the validity of the information about HPV vaccination in SSA.
A second central theme that emerged from this review was how beliefs around in-
fertility have created a significant divide in understandings of HPV vaccination in SSA.
Stakeholders tended to hold one of two opposing views of the causes of infertility. Some
attributed infertility to cervical cancer thus encouraging support for the HPV vaccine for
prevention of common cancer-causing strains of HPV and by extension, infertility. Con-
versely, others attributed infertility to the HPV vaccine itself, which fueled HPV vaccination
hesitancy and refusal amongst stakeholders who harbor such beliefs. This supports broader
findings that infertility amongst African women can have serious psychological and social
implications for women, along with being a major factor for marital instability, social
pressure and ostracization, stigmatization and abuse [56–59]. Examining perceptions that
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infertility can be caused by HPV vaccination is vital to understanding HPV vaccination
hesitancy in the African context.
A final theme that emerged from this review was the significant role that gender
dynamics play in how stakeholders perceive HPV vaccination. Gendered dynamics were
present in stakeholder perceptions and understandings of HPV vaccination in the following
ways; the notion that HPV vaccination can be a viable harm reduction strategy against
female gender-based violence, significant differences across countries in SSA in regard to
whom makes decisions within households about health seeking behaviors (such as HPV
vaccination), and finally, that female-only HPV vaccination campaigns encourages the
perception of HPV as a female specific issue which perpetuates misinformation. This is
aligned with the broader research examining the feminization of HPV due to the focus on
cervical cancer screening, which has not only made females the primary group responsible
for HPV prevention, but has also resulted insufficient protection from HPV-related illnesses
in males and females alike [55–57,60]. This review also supports the broader literature of
gendered disparities in HPV vaccination uptake by sex being consistent with the delayed
recommendation for boys to also get the HPV vaccine, and today, further evident in a lack of
coverage for boys in many National Insurance Programs with conflicting messages around
gender norms as both a barrier and facilitator to HPV vaccination uptake [55–57,60,61].
The findings from this review have various practical implications for how demand for
HPV vaccination might be enhanced. The dynamics of trust and drivers of distrust between
communal stakeholders and the government, medical and public health community need
to first be recognized and then be addressed through wide spread meaningful engagement.
Prior to rollout, education and social mobilization around the HPV vaccination Programs
should sufficiently engage communities in order to thoroughly gauge local understandings,
conceptions and misconceptions, language nuances, baseline perceptions and fears around
cervical cancer, HPV and HPV vaccination. Utilizing local language nuances of disease
terminology and recognized symptomology may be an important consideration for HPV
vaccination roll out strategies across SSA when shaping content and focus of education
and awareness-raising interventions [26,31–33,37,43]. Secondly, engagement with and
involvement of various social actors identified as trusted sources of information from the
community themselves, may facilitate improvements in stakeholder perceptions of HPV
vaccination in SSA. This is especially notable in the effort to mitigating the belief that
HPV vaccination causes infertility, the most prominent and wide-spread rumor across SSA.
Finally, implementation of HPV vaccination Programs without thorough understanding of
gender dynamics within the context of the specific country implementing HPV vaccina-
tion can potentially create roadblocks for HPV vaccination uptake, as well as perpetuate
confusion, misinformation, distrust and stigma. This is notable as this review found that,
depending on the country, health seeking behavior and decision making around HPV
vaccination were driven by either male or female head of households, suggesting that
locally appropriate interventions need to speak to country specific gender dynamics in
health seeking behavior.
Although some studies used focus group discussions and interviews to assess prelimi-
nary perceptions of cervical cancer, HPV, and HPV vaccination, often following up with
an educational component at the completion of the study to address misinformation, it is
evident that efforts to address misinformation require first understanding the social context
and the social dynamics within that context, as identified in this review. This supports
previous research that community acceptability towards HPV vaccination is a slow process
that requires first acknowledging rumors, fears, and concerns, prior to expressing the
benefits and safety of HPV vaccination [41]. This review supports prior research that calls
for strategies to first address prominent misinformation about HPV vaccination in the SSA
context prior to HPV vaccination campaign roll out [13,14,16,26,41], highlighting that HPV
vaccination decision-making is complex and multifactorial [60,61].
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4.1. Reflexivity
The lead researcher has a background in public health and acknowledges that this has
shaped positive attitudes towards vaccination more generally. As cervical cancer is largely
preventable, the lead researcher undertook this analysis in order to better understand
extreme rates of morbidity and mortality from HPV and cervical cancer in SSA [21].
4.2. Strengths and Limitations of the Rapid Qualitative Review
A strength of this review is the consideration and acknowledgement of divergent
findings within the dataset and what such conflicts reveal about understandings of HPV
vaccination in SSA. This review provides a ‘big picture’ demand-side perspective to con-
tribute to improvements in current and future HPV vaccination strategies in SSA, an
under-researched area overall.
This was a rapid qualitative review and thus has various limitations common to
this approach. Limitations include: a single review author for all stages of the search
strategy (although this limitation was addressed through a 20% random sampling of
title and abstracts and eligible full text studies, assessed by two independent reviewers).
A ‘Confidence in Evidence from Reviews of Qualitative Research’ assessment was not
conducted [62]. The date of studies ranges from 2006–2018, introducing the possibility
that some of the previously published literature is out of date compared to present-day.
Exclusion of grey literature is a limitation due to time and resource constraints, as well as
exclusion of non-English studies due to the language capacities of the review team.
5. Conclusions
Stakeholders who create a demand for the HPV vaccine are arguably the most vital to
its uptake and continued necessity, especially when the momentum of HPV vaccination
in SSA has only recently been initiated. How stakeholders understand cervical cancer,
HPV, and HPV vaccination will be vital to the short- and long-term success of HPV vac-
cination Programs in SSA. This review found that stakeholder understandings of HPV
vaccination are shaped by a complex relationship between knowledge and misinforma-
tion, a significant fear of infertility associated with both cervical cancer and the HPV
vaccine, and social and gender dynamics in SSA. This review iterates the importance of
first working with communities to gauge local and context-specific understandings, before
trying to implement change through one-size-fits all education, sensitization and behavior
change strategies.
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Appendix A. Search Strategy
PubMed
(“Papillomavirus Vaccines”[Mesh] OR “Human Papillomavirus Recombinant Vaccine
Quadrivalent, Types 6, 11, 16, 18”[Mesh]
OR
“human papillomavirus vaccine” OR “HPV vaccine” OR “human papillomavirus
vaccination” OR “HPV vaccination”
AND
“Health Knowledge, Attitudes, Practice”[Mesh]
OR
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Knowledge OR attitude OR attitudes OR belief OR beliefs OR perceptions OR percep-
tion
OR comprehend OR comprehension OR experience OR experiences OR understand
OR understandings OR feel OR feelings OR opinion OR opinions OR point of view OR
view OR views
AND
(“Africa”[Mesh] OR “Africa South of the Sahara”[Mesh] OR “Africa, Central”[Mesh] OR
“Cameroon”[Mesh] OR “Central African Republic”[Mesh] OR “Chad”[Mesh] OR “Congo”[Mesh]
OR “Democratic Republic of the Congo”[Mesh] OR “Equatorial Guinea”[Mesh]
OR “Gabon”[Mesh] OR “Sao Tome and Principe”[Mesh] OR “Africa, Eastern”[Mesh]
OR “Burundi”[Mesh] OR “Djibouti”[Mesh] OR “Eritrea”[Mesh] OR “Ethiopia”[Mesh] OR
“Kenya”[Mesh] OR “Rwanda”[Mesh] OR “Somalia”[Mesh] OR “South Sudan”[Mesh] OR
“Sudan”[Mesh] OR “Tanzania”[Mesh] OR “Uganda”[Mesh] OR “Africa, Southern”[Mesh]
OR “Angola”[Mesh] OR “Botswana”[Mesh] OR “Lesotho”[Mesh] OR “Malawi”[Mesh]
OR “Mozambique”[Mesh] OR “Namibia”[Mesh] OR “South Africa”[Mesh] OR “Swazi-
land”[Mesh] OR “Zambia”[Mesh] OR “Zimbabwe”[Mesh] OR “Africa, Western”[Mesh] OR
“Benin”[Mesh] OR “Burkina Faso”[Mesh] OR “Cabo Verde”[Mesh] OR “Cote d’Ivoire”[Mesh]
OR “Gambia”[Mesh] OR “Ghana”[Mesh] OR “Guinea”[Mesh] OR “Guinea-Bissau”[Mesh]
OR “Liberia”[Mesh] OR “Mali”[Mesh] OR “Mauritania”[Mesh] OR “Niger”[Mesh] OR
“Nigeria”[Mesh] OR “Senegal”[Mesh] OR “Sierra Leone”[Mesh] OR “Togo”[Mesh])
OR
“Africa” OR “Sub Saharan Africa” OR “ Central Africa “ OR “Cameroon” OR “Central
African Republic” OR “Chad” OR “Congo” OR “Democratic Republic of the Congo” OR
“Equatorial Guinea” OR “Gabon” OR “Sao Tome and Principe” OR “ Eastern Africa “ OR
“East Africa” OR “Burundi” OR “Djibouti” OR “Eritrea” OR “Ethiopia” OR “Kenya” OR
“Rwanda” OR “Somalia” OR “South Sudan” OR “Sudan” OR “Tanzania” OR “Uganda”
OR “ Southern Africa” OR “Angola” OR “Botswana” OR “Lesotho” OR “Malawi” OR
“Mozambique” OR “Namibia” OR “South Africa” OR “Swaziland” OR “Zambia” OR
“Zimbabwe” OR “ Western Africa” OR “West Africa” OR “Benin” OR “Burkina Faso” OR
“Cabo Verde” OR “Cote d’Ivoire” OR “Gambia” OR “Ghana” OR “Guinea” OR “Guinea-
Bissau” OR “Liberia” OR “Mali” OR “Mauritania” OR “Niger” OR “Nigeria” OR “Senegal”
OR “Sierra Leone” OR “Togo”
AND
“Qualitative Research” [Mesh] OR qualitative research OR “Empirical Research”
[Mesh] OR “Focus Groups” [Mesh] OR “Interviews as Topic”[Mesh] OR “Observational
Studies as Topic”[Mesh] OR “Observational Study” [Publication Type]
OR
“empirical research” OR interviews OR “focus groups” OR “observational studies”
OR “thematic analysis” OR Ethnography OR “meta-ethnography”
Other Databases




“human papillomavirus vaccine” OR “HPV vaccine” OR “human papillomavirus
vaccination” OR “HPV vaccination”
AND
Knowledge OR attitude OR attitudes OR belief OR beliefs OR perceptions OR percep-
tion OR comprehend OR comprehension OR experience OR experiences OR understand
OR understandings OR feel OR feelings OR opinion OR opinions OR point of view OR
view OR views OR decision OR decisions
AND
“Africa” OR “Sub Saharan Africa” OR “ Central Africa “ OR “Cameroon” OR “Central
African Republic” OR “Chad” OR “Congo” OR “Democratic Republic of the Congo” OR
Vaccines 2021, 9, 496 15 of 21
“Equatorial Guinea” OR “Gabon” OR “Sao Tome and Principe” OR “ Eastern Africa “ OR
“East Africa” OR “Burundi” OR “Djibouti” OR “Eritrea” OR “Ethiopia” OR “Kenya” OR
“Rwanda” OR “Somalia” OR “South Sudan” OR “Sudan” OR “Tanzania” OR “Uganda”
OR “ Southern Africa” OR “Angola” OR “Botswana” OR “Lesotho” OR “Malawi” OR
“Mozambique” OR “Namibia” OR “South Africa” OR “Swaziland” OR “Zambia” OR
“Zimbabwe” OR “ Western Africa” OR “West Africa” OR “Benin” OR “Burkina Faso” OR
“Cabo Verde” OR “Cote d’Ivoire” OR “Gambia” OR “Ghana” OR “Guinea” OR “Guinea-
Bissau” OR “Liberia” OR “Mali” OR “Mauritania” OR “Niger” OR “Nigeria” OR “Senegal”
OR “Sierra Leone” OR “Togo”
AND
Qualitative research OR empirical research OR interviews OR focus groups OR obser-
vational studies OR thematic analysis OR Ethnography OR meta-ethnography
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Balogun, 2018 Yes Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes
Bingham, 2009 Yes Yes Yes Yes Yes No Yes Can’t tell Yes Can’t tell
Crann, 2016 Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes Yes
Francis, 2011 Yes Yes Yes Yes Yes Yes No Yes Yes Can’t tell
Francis, 2013 Yes Yes Yes Yes Yes No Can’t tell No Can’t tell Yes
Friedman, 2014 Yes Yes Yes Yes Yes No Can’t tell Can’t tell No Yes
Gallagher, 2018 Yes Yes Yes Yes Yes No Can’t tell Can’t tell Yes Yes
Gallagher,
2018b
Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes
Harries, 2009 Yes Yes Yes Yes Yes Yes Can’t tell Yes Can’t tell Yes
Hasahya, 2016 Yes Yes Yes Yes Yes Can’t tell Yes Can’t tell Can’t tell Can’t tell
Kamya, 2017 Yes Yes Yes Yes Yes Yes No No Yes Yes
Katahoire, 2008 Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes
Katahoire, 2013 Yes Yes Yes Yes Yes No Yes Can’t tell Yes Yes
Katz, 2013 Yes Yes Yes Yes Yes No Yes Can’t tell No Yes
Kisaakye, 2018 Yes Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes
Masika, 2015 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Mugisha, 2015 Yes Yes Yes Yes Yes Yes No No Yes Yes
Nelson 2010 Yes Yes Yes Yes Yes Can’t tell Yes No Yes Yes
Nambe 2018 Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes
Ports, 2013 Yes Yes Yes Yes Yes Yes Yes No Yes Yes
Remes, 2012 Yes Yes Yes Yes Yes Yes Yes No Can’t tell Can’t tell
Soi, 2018 Yes Yes Yes Yes Yes Can’t tell No Yes Yes Yes
Tuhiro, 2014 Yes Yes Yes Yes Yes Yes No Can’t tell Yes Yes
Tuhiro, 2017 Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes
Venturas, 2017 Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes Yes
Vermandere,
2015
Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes Yes
Vermandere,
2016
Yes Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes
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Vielot, 2017 Yes Yes Yes Yes Yes No Yes Can’t tell Yes Yes
Watson-Jones,
2016
Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes
Watson-Jones,
2015
Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes Yes
Yasmine Islam,
2018
Yes Yes Yes Yes Yes No Yes Yes Yes Yes
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